Authors: Sharon Salt, Editor
In a large clinical trial to determine the risks and benefits of daily low-dose aspirin in healthy older adults without previous cardiovascular events, aspirin did not prolong healthy, independent living free of dementia or physical disability.
These initial findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial were published online in three papers in The New England Journal of Medicine, which can be found below.
ASPREE is an international, randomized, double-blind, placebo-controlled trial that enrolled 16,703 individuals in Australia and 2411 in the USA. At the study enrollment, ASPREE participants could not have dementia or a physical disability and had to be free of medical conditions requiring aspirin use. They were followed for an average 4.7 years to determine outcomes.